ClearPoint Neuro (NASDAQ:CLPT) Director Sells $185,440.00 in Stock

ClearPoint Neuro, Inc. (NASDAQ:CLPT) Director Matthew Klein sold 16,000 shares of the business’s stock in a transaction on Thursday, May 21st. The shares were sold at an average price of $11.59, for a total transaction of $185,440.00. Following the completion of the sale, the director directly owned 46,935 shares of the company’s stock, valued at approximately $543,976.65. This trade represents a 25.42% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

ClearPoint Neuro Price Performance

Shares of CLPT opened at $12.24 on Friday. ClearPoint Neuro, Inc. has a 1-year low of $8.27 and a 1-year high of $30.10. The stock has a market cap of $367.08 million, a PE ratio of -12.12 and a beta of 1.29. The company has a debt-to-equity ratio of 2.63, a current ratio of 5.79 and a quick ratio of 4.88. The firm has a fifty day moving average price of $10.60 and a 200 day moving average price of $12.60.

ClearPoint Neuro (NASDAQ:CLPT) last announced its quarterly earnings results on Wednesday, May 13th. The company reported ($0.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.04). ClearPoint Neuro had a negative net margin of 71.57% and a negative return on equity of 140.96%. The company had revenue of $12.13 million during the quarter, compared to analysts’ expectations of $11.97 million. As a group, sell-side analysts anticipate that ClearPoint Neuro, Inc. will post -1.05 EPS for the current year.

Wall Street Analysts Forecast Growth

CLPT has been the subject of a number of research reports. B. Riley Financial boosted their price target on shares of ClearPoint Neuro from $18.00 to $20.00 and gave the company a “buy” rating in a research report on Wednesday, March 18th. Weiss Ratings reissued a “sell (d-)” rating on shares of ClearPoint Neuro in a research report on Monday, April 20th. Finally, Stifel Nicolaus assumed coverage on shares of ClearPoint Neuro in a report on Friday, May 8th. They issued a “buy” rating and a $16.00 target price for the company. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $18.00.

Institutional Investors Weigh In On ClearPoint Neuro

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Caitong International Asset Management Co. Ltd acquired a new position in shares of ClearPoint Neuro in the fourth quarter valued at approximately $25,000. Huntington National Bank acquired a new position in shares of ClearPoint Neuro in the third quarter valued at approximately $44,000. BNP Paribas Financial Markets increased its holdings in shares of ClearPoint Neuro by 2,435.2% in the second quarter. BNP Paribas Financial Markets now owns 2,231 shares of the company’s stock valued at $27,000 after purchasing an additional 2,143 shares during the period. Russell Investments Group Ltd. increased its holdings in shares of ClearPoint Neuro by 1,079.0% in the third quarter. Russell Investments Group Ltd. now owns 2,358 shares of the company’s stock valued at $51,000 after purchasing an additional 2,158 shares during the period. Finally, Legal & General Group Plc acquired a new position in shares of ClearPoint Neuro in the second quarter valued at approximately $35,000. 30.08% of the stock is owned by hedge funds and other institutional investors.

ClearPoint Neuro Company Profile

ClearPoint Neuro, Inc is a medical technology company specializing in the development and commercialization of an MRI-guided therapy platform for minimally invasive neurosurgical procedures. Headquartered in Cambridge, Massachusetts, the company’s flagship ClearPoint® SmartFrame™ system enables surgeons to perform accurate and efficient intracranial interventions by providing real-time magnetic resonance imaging feedback. This technology is designed to improve patient safety and outcomes in treatments ranging from deep brain stimulation electrode placement to laser ablation of epileptic foci and brain tumors.

The ClearPoint System integrates hardware, software and imaging capabilities to guide instruments through the brain with submillimeter precision.